EDGEWISE THERAPEUTICS ANNOUNCES POSITIVE TWO-YEAR TOPLINE RESULTS

Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)

– The North Star Ambulatory Assessment (NSAA) remained stable relative to declines reported in Becker natural history studies –

– Significant decreases were observed in circulating levels of creatine kinase (CK) and fast skeletal muscle troponin I (TNNI2), biomarkers associated with skeletal muscle damage –

– Sevasemten was well-tolerated –

– Edgewise leadership to discuss ARCH findings on Tuesday, April 16 at 8:30 a.m. Eastern Time at virtual investor event –

Read the full press release HERE